Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Net Income towards Common Stockholders for 5 consecutive years, with -$9.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Net Income towards Common Stockholders fell 33.36% year-over-year to -$9.8 million, compared with a TTM value of -$9.8 million through Dec 2025, up 70.04%, and an annual FY2025 reading of -$47.8 million, down 40.04% over the prior year.
  • Net Income towards Common Stockholders was -$9.8 million for Q2 2025 at SAB Biotherapeutics, up from -$9.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.4 million in Q1 2021 and bottomed at -$22.9 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$7.1 million, with a median of -$7.1 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders crashed 845.93% in 2023, then surged 56.5% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then crashed by 190.26% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then grew by 1.61% to -$9.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for SABS at -$9.8 million in Q2 2025, -$9.9 million in Q4 2024, and -$10.3 million in Q3 2024.